clofibric acid has been researched along with HIV-Associated Lipodystrophy Syndrome in 1 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
Excerpt | Relevance | Reference |
---|---|---|
" Dyslipidemia in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis may improve with use of statins, fibrates, niacin, and thiazolidinediones, but the data are presently very limited." | 4.82 | Management of dyslipidemia in patients with complicated metabolic syndrome. ( Davidson, MH, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davidson, MH | 1 |
1 review available for clofibric acid and HIV-Associated Lipodystrophy Syndrome
Article | Year |
---|---|
Management of dyslipidemia in patients with complicated metabolic syndrome.
Topics: Clofibric Acid; Fatty Liver; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-Co | 2005 |